Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

The Clinical Effect of Botulinum Toxin in a Patient with Tourette's Syndrome: A Case Report and Review

뚜렛 증후군에서 보툴리눔 톡신의 임상 효과 : 증례보고 및 고찰

  • Hyun, Jung Keun (Department of Rehabilitation, College of Medicine, Dankook University) ;
  • Lee, Jun Hyung (Department of Psychiatry, College of Medicine, Dankook University) ;
  • Lee, Chang Min (Department of Neurology, College of Medicine, Dankook University) ;
  • Lim, Myung Ho (Department of Psychiatry, College of Medicine, Dankook University)
  • 현정근 (단국대학교 의과대학 재활의학교실) ;
  • 이준형 (단국대학교 의과대학 정신건강의학교실) ;
  • 이창민 (단국대학교 의과대학 신경과학교실) ;
  • 임명호 (단국대학교 의과대학 정신건강의학교실)
  • Received : 2013.04.02
  • Accepted : 2013.05.28
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Botulinum toxin, a neurotoxin, is known to be an inhibitor of cholinergic neuromuscular transmission. Recently, it was reported that the administration of botulinum toxin is effective for the treatment of focal neurological motor disorders such as cervical dystonia, blepharospasm, hemifacial spasm, spasmodic dysphonia, and writer's cramp. Several case studies reported that the botulinum toxin was administered for the treatment of motor tic or vocal tic. It was found that this toxin reduces the frequency and severity of the tic as well as the premonitory urge and symptoms. In our case study, a noticeable decrease of motor tic symptom was observed after an intramuscular injection of 300mg of botulinum toxin in an 18-year-old patient with Tourette's disorder who showed only a little improvement of motor tic and vocal tic symptoms after treatment with antipsychotic drugs for several years. This case is reported in our study and literature survey was undertaken for reviewing similar cases. In our study, an 18-year-old boy diagnosed with Tourette's disorder based on Diagnostic and Statistical Manual of Mental Disorders, fourth edition presented with the following scores : the Clinical Global Impression scale, Yale Global Tic Severity Scale (motor/vocal/severity), Premonitory Urge Score, Korean Attention-Deficit Hyperactivity Disorder Rating scale, and Kovac Depression scale which were performed prior to the treatment were 5, 21/5/50, 100, 17, and 18 points, respectively. Two weeks after the injection of botulinum toxin, the scores were 4, 17/5/40, 50, 16, and 19 points, respectively. Eight weeks after the injection of botulinum toxin, they had become 3, 15/5/30, 25, 16, and 20 points, respectively, which clearly indicates a noticeable decrease of motor tic symptom.

Keywords

References

  1. American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders Text Revision 4th. ed. Washington, DC: American Psychiatric Association Press;2002.
  2. Singer HS. Tourette's syndrome: from behaviour to biology. Lancet Neurol 2005;4:149-159. https://doi.org/10.1016/S1474-4422(05)01012-4
  3. Kurlan R, McDermott MP, Deeley C, Como PG, Brower C, Eapen S, et al. Prevalence of tics in schoolchildren and association with placement in special education. Neurology 2001;57:1383-1388. https://doi.org/10.1212/WNL.57.8.1383
  4. Gadow KD, Nolan EE, Sprafkin J, Schwartz J. Tics and psychiatric comorbidity in children and adolescents. Dev Med Child Neurol 2002;44:330-338.
  5. George MS, Belmaker RH. Transcranial Magnetic Stimulation in Clinical Psychiatry. Washington, DC: American Psychiatric Publishing;2007.
  6. Mink JW. Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs. Adv Neurol 2006;99:89-98.
  7. Truong DD, Jost WH. Botulinum toxin: clinical use. Parkinsonism Relat Disord 2006;12:331-355. https://doi.org/10.1016/j.parkreldis.2006.06.002
  8. Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord 1996;11:431-433. https://doi.org/10.1002/mds.870110413
  9. Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord 1996;11:563-566. https://doi.org/10.1002/mds.870110512
  10. Trimble MR, Whurr R, Brookes G, Robertson MM. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 1998;13:617-619. https://doi.org/10.1002/mds.870130348
  11. Salloway S, Stewart CF, Israeli L, Morales X, Rasmussen S, Blitzer A, et al. Botulinum toxin for refractory vocal tics. Mov Disord 1996; 11:746-748. https://doi.org/10.1002/mds.870110627
  12. Jankovic J. Botulinum toxin in movement disorders. Curr Opin Neurol 1994;7:358-366. https://doi.org/10.1097/00019052-199408000-00014
  13. Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 2000;57:1190-1193. https://doi.org/10.1001/archneur.57.8.1190
  14. Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci 2004;24:420-423. https://doi.org/10.1007/s10072-003-0201-4
  15. Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001;56:605-610. https://doi.org/10.1212/WNL.56.5.605
  16. Guy W. ECDU Asessment Manual for Psychopharmacology, Revised. Bethesda: US Department of Health, Education, and Welfare;1976.
  17. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician- rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566-573. https://doi.org/10.1097/00004583-198907000-00015
  18. Kovacs M. The children's depression inventory: a self-rated depression scale for school-aged youngsters. Unpublished manuscript. Pittsburgh, PA: University of Pittsburgh;1983.
  19. Cho SC, Choi JS. Development of Korean form of the State-Trait Anxiety Inventory for children. J Seoul Psychitr 1989;14:150-157.
  20. Kim YS, So YK, Noh JS, Choi NK, Kim SJ, Ko YJ. The reliability and validity of Korean Parent and Teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc 2002;41:283-289.
  21. Brin MF, Dressler D, Aoki R. Pharmacology of botulinum toxin therapy. In: Jankovic J, Comella C, Brin MF, editors. Dystonia: Etiology, Clinical Features, and Treatment. Philadelphia: Lippincott Williams & Wilkins;2004. p.93-112.
  22. Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol 2012;15:325-336. https://doi.org/10.1016/j.mib.2012.05.012
  23. Probst TE, Heise H, Heise P, Benecke R, Dressler D. Rare immunologic side effects of botulinum toxin therapy: brachial plexus neuropathy and dermatomyositis. Mov Disord 2002;17(Suppl 5):S49.
  24. Burguera JA, Villaroya T, Lopez-Alemany M. Polyradiculoneuritis after botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol 2000;23:226-228. https://doi.org/10.1097/00002826-200007000-00012
  25. Erbguth F, Claus D, Engelhardt A, Dressler D. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1993; 56:1235-1236. https://doi.org/10.1136/jnnp.56.11.1235
  26. Shapiro AK, Shapiro ES, Bruun RD, Sweet RD. Gilles de la Tourette Syndrome. New York: Ravan;1998. p.146-149.
  27. Erenberg G, Cruse RP, Rothner AD. The natural history of Tourette syndrome: a follow-up study. Ann Neurol 1987;22:383-385. https://doi.org/10.1002/ana.410220317
  28. Bruun RD, Budman CL. The course and prognosis of Tourette syndrome. In: Jankovic J, editor. Tourette Syndrome: Neurologic Clinics. Philadelphia: WB Saunders;1997. p.291-296.
  29. Leckman JF, Peterson BS, Anderson GM, Arnsten AF, Pauls DL, Cohen DJ. Pathogenesis of Tourette's syndrome. J Child Psychol Psychiatry 1997;38:119-142. https://doi.org/10.1111/j.1469-7610.1997.tb01508.x
  30. Bliss J. Sensory experiences of Gilles de la Tourette syndrome. Arch Gen Psychiatry 1980;37:1343-1347. https://doi.org/10.1001/archpsyc.1980.01780250029002
  31. Lang A. Patient perception of tics and other movement disorders. Neurology 1991;41(2 (Pt 1)):223-228. https://doi.org/10.1212/WNL.41.2_Part_1.223
  32. Dressler D, Adib Saberi F. First high dose use of complex free botulinum toxin type A. Mov Disord 2006;21(Suppl 15):S640.